Skip to content
drybagdenim

drybagdenim

drybagdenim

  • Home
  • Music
  • Human activities
  • Sports
  • Finance
  • Toggle search form

Thermo Fisher Scientific Inc. (NYSE: TMO) is Seelaus Asset Management LLC’s 6th Largest Position:

Posted on June 24, 2022 By admin No Comments on Thermo Fisher Scientific Inc. (NYSE: TMO) is Seelaus Asset Management LLC’s 6th Largest Position:

Seelaus Asset Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) by 7.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,659 shares of the medical research company stock after selling 390 shares during the quarter. Thermo Fisher Scientific accounts for 1.6% of Seelaus Asset Management LLC’s investment portfolio, making the stock its 6th largest position. Seelaus Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $ 2,752,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Thermo Fisher Scientific by 3.8% in the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company stock worth $ 20,672,838,000 after acquiring an additional 1,143,333 shares during the last quarter. State Street Corp lifted its holdings in shares of Thermo Fisher Scientific by 3.4% in the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company stock worth $ 10,828,875,000 after acquiring an additional 529,712 shares during the last quarter. Capital Research Global Investors lifted its holdings in shares of Thermo Fisher Scientific by 2.3% in the 4th quarter. Capital Research Global Investors now owns 9,454,032 shares of the medical research company stock worth $ 6,308,097,000 after acquiring an additional 208,075 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 6,403,805 shares of the medical research company stock worth $ 4,261,136,000 after buying an additional 214,375 shares in the last quarter. Finally, Norges Bank acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $ 2,784,029,000. Hedge funds and other institutional investors own 87.48% of the company stock.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $ 545.60, for a total transaction of $ 5,456,000.00. Following the transaction, the chief executive officer now directly owns 183,373 shares of the company stock, valued at approximately $ 100,048,308.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Debora L. Spar sold 200 shares of the firm’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $ 544.36, for a total transaction of $ 108,872.00. Following the transaction, the director now directly owns 810 shares in the company, valued at $ 440,931.60. The disclosure for this sale can be found here. Insiders have sold a total of 42,561 shares of company stock worth $ 23,557,413 over the last three months. 0.43% of the stock is currently owned by insiders.

A number of equities research analysts have issued reports on TMO shares. StockNews.com started coverage on shares of Thermo Fisher Scientific in a report on Thursday, March 31st. They set a “hold” rating on the stock. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $ 605.00 to $ 525.00 in a report on Monday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $ 658.92.

NYSE TMO opened at $ 519.22 on Thursday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10. The firm’s fifty day moving average price is $ 544.31 and its 200 day moving average price is $ 575.26. The company has a market capitalization of $ 203.25 billion, a price-to-earnings ratio of 27.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 12 month low of $ 489.14 and a 12 month high of $ 672.34.

Thermo Fisher Scientific (NYSE: TMO – Get Rating) last posted its earnings results on Thursday, April 28th. The medical research company reported $ 7.25 EPS for the quarter, beating analysts’ consensus estimates of $ 6.17 by $ 1.08. The firm had revenue of $ 11.82 billion for the quarter, compared to the estimate consensus of $ 10.66 billion. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The company revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm posted $ 7.21 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 22.7 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 15th. Shareholders of record on Wednesday, June 15th will be given a dividend of $ 0.30 per share. This represents a $ 1.20 annualized dividend and a yield of 0.23%. The ex-dividend date is Tuesday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 6.26%.

Thermo Fisher Scientific Profile: (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories:

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE: TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Finance Tags:13F:, 88355610:, Hedge Fund Holdings:, Institutional Investor Holdings:, Medical:, NYSE: TMO:, SEC Filings:, Thermo Fisher Scientific:, TMO:

Post navigation

Previous Post: Cantor Fitzgerald Investment Advisor LP Has $ 1.69 Million Stake in The Coca-Cola Company (NYSE: KO)
Next Post: Tesla, Inc. (NASDAQ: TSLA) Shares Purchased by Flagship Harbor Advisors LLC:

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Archives

  • June 2022

Categories

  • Finance
  • Human activities
  • Music
  • Sports

Recent Posts

  • Thermo Fisher Scientific Inc. (NYSE: TMO) Shares Bought by Wealthcare Advisory Partners LLC:
  • Ritholtz Wealth Management Sells 310 Shares of The Estée Lauder Companies Inc. (NYSE: EL)
  • Johnson & Johnson (NYSE: JNJ) is Bar Harbor Trust Services’ Largest Position:
  • Private Trust Co. NA Has $ 40.87 Million Stock Position in Apple Inc. (NASDAQ: AAPL)
  • Head-To-Head Contrast: WesBanco (NASDAQ: WSBC) vs. CF Bankshares (NASDAQ: CFBK)

Recent Comments

No comments to show.
  • About us
  • Contact us
  • DMCA
  • Privacy policy
  • Terms and conditions

Copyright © 2022 drybagdenim.

Powered by PressBook WordPress theme